Appili Therapeutics, Inc. was specifically founded to advance the global fight against infectious disease by matching clearly-defined medical needs with drug development programs and funding mechanisms that allow the company to accelerate the availability of improved anti-infective solutions or produce entirely novel agents.
The Appili team follows a rigorous process to identify and evaluate drug development opportunities, and to ensure that they align optimally with market need. Because the company is not bound to a specific technology or platform, the team is able to consider a wide range of additions to its pipeline, and target programs that rapidly generate value or, in time, represent significant advances in the treatment of infectious diseases.
This flexibility also allows Appili to pursue development opportunities that provide access to non-dilutive funding from government incentive programs or industry partnerships. An important aspect of this approach to portfolio building is discipline – Appili’s team has reviewed and passed on over 100 drug development projects that did not meet its scientific, clinical, patient-care and financial criteria.
In response to the global threat of increasingly resistant or difficult-to-treat infectious diseases, federal agencies have created a number of special programs and incentives to encourage the development of new anti-infectives.